Brief: Mineralys Therapeutics Announces Expansion Of Planned Phase 2 Trial Of Lorundrostat Alone And In Combination With SGLT2 Inhibitor To Treat Patients With Chronic Kidney Disease

Mineralys Therapeutics

17/07/2023 21:15

July 17 (Reuters) - Mineralys Therapeutics Inc  MLYS.O :
    * MINERALYS THERAPEUTICS ANNOUNCES EXPANSION OF PLANNED
PHASE 2
TRIAL OF LORUNDROSTAT ALONE AND IN COMBINATION WITH SGLT2
INHIBITOR TO TREAT PATIENTS WITH CHRONIC KIDNEY DISEASE (CKD)
    * MINERALYS THERAPEUTICS - PROFILING TRIAL OF SAFETY IN
INDIVIDUALS WITH STAGE 3B AND 4 CKD TO SUPPORT HYPERTENSION
INDICATION WILL BE RUN IN PARALLEL
    * MINERALYS THERAPEUTICS INC - TOPLINE DATA FROM THIS TRIAL
IS
ANTICIPATED BETWEEN Q4 2024 AND Q1 2025
    * MINERALYS THERAPEUTICS-PLAN TO INITIATE PHASE 2 PROOF OF
CONCEPT
TRIAL OF LORUNDROSTAT ALONE & IN COMBINATION WITH SGLT2
INHIBITOR FOR CKD IN H2 2023

Source text for Eikon:  ID:nGNX8K0rFk 
Further company coverage:  MLYS.O 

 (Reuters.Briefs@thomsonreuters.com)